RGNT$1.38+0.73%
Regentis Biomaterials Ltd.
Sector: Orthopedic, Prosthetic & Surgical Appliances & SuppliesIndustry: Medical - Instruments & SuppliesCountry: ILExchange: NYSE
Mkt Cap:$9.69M
Float & O/S:
Inst Own:
DilutionScan read 40 of REGENTIS BIOMATERIALS LTD.'s SEC filings and found 10 warrant series, 3 convertibles, 3 S-1 registrations and 2 completed offerings on file for RGNT. The latest dilution event on file is a registration statement on Jul 13, 2026. Analysis updated Oct 4, 2026.
Signal8 Summary
RGNT
Unprofitable micro-cap near 52-week low
Snapshot
Regentis is a tiny, unprofitable biotech company with a $17.5M market cap. The stock is trading near its 52-week low at $1.28, down 84.7% from its high of $8.35. The company has no revenue and reports massive losses, with an EPS of -$24.16.
What's Happening Right Now
- : Regentis plans to start training European surgeons for its GelrinC knee implant in Q3 2026, accelerating commercial rollout in the EU where it already has approval.
- : Regentis reported that its pivotal FDA study for GelrinC in the US has completed over 50% of patient enrollment, targeting a $3 billion market.
- : The company patented a new solvent-free manufacturing process that increases GelrinC production yield by 400%, a key step before the European launch.
